跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

E-068

Supelco

依维莫司 溶液

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C53H83NO14
CAS号:
159351-69-6
分子量:
958.22
MDL號碼:
MFCD00929329
分類程式碼代碼:
41116107
PubChem物質ID:
329798983
NACRES:
NA.24

等級

certified reference material

品質等級

300

形狀

liquid

特點

(Snap-N-Spike®)

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

濃度

1.0 mg/mL in acetonitrile

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

形式

single component solution

運輸包裝

dry ice

儲存溫度

−70°C

SMILES 字串

N21[C@@H](CCCC2)C(=O)O[C@@H](CC(=O)[C@@H](\C=C(\[C@H]([C@H](C(=O)[C@@H](C[C@@H](\C=C\C=C\C=C(\[C@H](C[C@H]4O[C@]([C@@H](CC4)C)(C(=O)C1=O)O)OC)/C)C)C)OC)O)/C)C)[C@@H](C[C@H]3C[C@H]([C@@H](CC3)OCCO)OC)C

InChI

1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1

InChI 密鑰

HKVAMNSJSFKALM-GKUWKFKPSA-N

基因資訊

human ... FKBP1A(2280)

相关类别

一般說明

以Zortress®、Certican和Afinitor®等商品名出售的依维莫司是一种免疫抑制剂，可用于防止器官移植排斥并治疗肾细胞癌和其他肿瘤。此认证加标溶液®适合用作从校准物、对照品或线性标准品的起始材料，通过LC/MS或GC/MS对患者全血样品中的依维莫司进行治疗性药物监测或临床和诊断检验。

應用


  • 依维莫司治疗肝母细胞瘤：研究表明，依维莫司可诱导肝母细胞瘤细胞发生自噬依赖性铁变态反应，凸显了其作为肿瘤研究治疗剂的潜力。本研究提供了依维莫司通过细胞死亡途径靶向癌细胞的机制（Huang et al., 2024）。

  • 了解mTOR抑制剂对口腔黏膜的损伤：一种新的假设认为，与依维莫司等mTOR抑制剂相关的口腔黏膜损伤是由于细胞应激和凋亡途径的破坏。该研究强调了在癌症和免疫抑制等疾病的靶向治疗背景下了解副作用的重要性（Sonis and Villa, 2023）。

  • 依维莫司胶束配方治疗神经系统疾病：Everolimus （RAD001）是一种稳定的胶束制剂，用于脑室内给药，旨在治疗阿尔茨海默病和其他神经系统疾病。该配方允许直接脑给药，潜在地提高药物的疗效和安全性（Gianessi et al., 2023）。

  • 癫痫治疗中的药代动力学：研究了依维莫司在局灶性皮质发育不良伴癫痫发作患者中的群体药代动力学。该研究有助于了解药物在特定神经环境下的行为，为剂量调整和治疗监测奠定了基础（Park et al., 2023）。

法律資訊

Afinitor is a registered trademark of Novartis AG
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zortress is a registered trademark of Novartis AG

象形圖

FlameExclamation mark
GHS02,GHS07

訊號詞

Danger

危險分類

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

35.6 °F - closed cup

閃點（°C）

2.0 °C - closed cup

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Ian T Meredith et al.
The American journal of cardiology, 113(7), 1117-1123 (2014-02-18)
In the randomized PLATINUM trial, the PROMUS Element platinum-chromium everolimus-eluting stent (PtCr-EES; Boston Scientific, Natick, Massachusetts) was noninferior to the XIENCE V cobalt-chromium everolimus-eluting stent (CoCr-EES; Boston Scientific and Abbott Vascular, Santa Clara, California) for the primary end point of
L M Neri et al.
Leukemia, 28(4), 739-748 (2013-07-31)
B-precursor acute lymphoblastic leukemia (B-pre ALL) is a malignant disorder characterized by the abnormal proliferation of B-cell progenitors. The prognosis of B-pre ALL has improved in pediatric patients, but the outcome is much less successful in adults. Constitutive activation of
Catherine Lombard-Bohas et al.
Bulletin du cancer, 101(2), 175-183 (2014-02-22)
Medical management of pancreatic neuroendocrine tumors has recently been improved by new molecules of which the mTOR inhibitor everolimus. If digestive neuroendocrine tumors are rare, the incidence is in constant increase and the prevalence in digestive cancers put them right
Masanori Taniwaki et al.
Journal of the American College of Cardiology, 63(16), 1617-1625 (2014-02-18)
The aim of the study was to investigate 4-year outcomes and predictors of repeat revascularization in patients treated with the Resolute zotarolimus-eluting stent (R-ZES) (Medtronic, Minneapolis, Minnesota) and XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, Abbott Park, Illinois) in the
Matteo Santoni et al.
Biochimica et biophysica acta, 1845(2), 221-231 (2014-02-01)
The mammalian target of rapamycin (mTOR) has emerged as an attractive cancer therapeutic target. Treatment of metastatic renal cell carcinoma (mRCC) has improved significantly with the advent of agents targeting the mTOR pathway, such as temsirolimus and everolimus. Unfortunately, a
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门